YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

1-Furan-2-yl-3-Pyridine-2-yl-Propenone Inhibits TNF-${\apha}$-induced Intestinal Inflammation via Suppression of MCP-1 and IL-8 Expressions in HT-29 Human Colon Epithelial Cells

1-Furan-2-yl-3-pyridin-2-yl-propenone의 TNF-${\apha}$ 유도성 MCP-1과 IL-8의 발현 억제를 통한 장 상피세포 염증 억제효과

  • Published : 2008.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Previously, we have shown that 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) has an anti-inflammatory activity in a rat paw-edema model. In the present study, we investigated an inhibitory effect of FPP-3 on the tumor necrosis factor (TNF)-${\apha}$-induced inflammatory cytokine response in HT-29 human colon epithelial cells. Treatment with FPP-3 significantly prevented the TNF-${\apha}$-induced attachment of leukocytes to HT-29 colon epithelial cells, which is one of the pathologic hallmarks in colon inflammation. The effect of FPP-3 was markedly superior than that of 5-aminosalicylic acid (5-ASA), a commonly used drug for the treatment of inflammatory bowel disease (IBD). The pretreatment with FPP-3 inhibited TNF-${\apha}$- induced monocyte chemoattractant protein (MCP)-1, interleukin (IL)-8 mRNA expressions. In addition, FPP-3 significantly suppressed TNF-${\apha}$-induced nuclear factor (NF)-${\kappa}B$ transcription activity. These results demonstrate that FPP-3 modulates intestinal inflammation via suppressing the NF-${\kappa}B$ dependent expressions of MCP-1 and IL-8, and suggest that FPP-3 may be a valuable agent for the treatment of IBD.

Keywords

References

  1. Ito, R., Shin-Ya, M., Kishida, T., Urano, A., Takada, R., Sakagami, J., Imanishi, J., Kita, M., Ueda, Y., Iwakura, Y., Kataoka, K., Okanoue, T. and Mazda, O. : Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 46, 330 (2006)
  2. Banks, C., Bateman, A., Payne, R., Johnson, P. and Sheron, N. : Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199, 28 (2003) https://doi.org/10.1002/path.1245
  3. Dijkstra, G., Moshage, H. and Jansen, P. L. : Blockade of NFkappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease. Scand J. Gastroenterol. Suppl. 236, 37 (2002)
  4. Lee, E. S., Park, B. C., Paek, S. H., Lee, Y. S., Basnet, A., Jin, D. Q., Choi, H. G., Yong, C. S. and Kim, J. A. : Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-ylpropenone with gastric ulcer sparing effect. Biol. Pharm. Bull. 29, 361 (2006) https://doi.org/10.1248/bpb.29.361
  5. Park, B. C., Thapa, D., Lee, Y. S., Kwak, M. K., Lee, E. S., Choi, H. G., Yong, C. S. and Kim, J. A. : 1-Furan-2-yl-3-pyridin- 2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP. Eur. J. Pharmacol. 567, 193 (2007) https://doi.org/10.1016/j.ejphar.2007.04.014
  6. Moon, Y., Yang, H. and Park, S. H. : Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol. Toxicol. Appl. Pharmacol. 15, 231 (2008)